The Report “ Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023 ”
The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period.
This study involved four major activities to estimate the current size of the cell surface markers market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.
Secondary Research
Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell surface markers market. Secondary sources such as The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), American Medical Association (AMA), Association of Medical Laboratory Immunologists (AMLI), National Cancer Institute (NCI), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Medicines Agency (EMA), and the British Society for Immunology (BSI) were used.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market.
Read More
Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US). Know more about Key Players
The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period.
This study involved four major activities to estimate the current size of the cell surface markers market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.
Secondary Research
Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell surface markers market. Secondary sources such as The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), American Medical Association (AMA), Association of Medical Laboratory Immunologists (AMLI), National Cancer Institute (NCI), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Medicines Agency (EMA), and the British Society for Immunology (BSI) were used.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market.
Read More
Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US). Know more about Key Players
Comments
Post a Comment